Robert W. Baird Reiterates “Buy” Rating for Myovant Sciences Ltd (MYOV)
Myovant Sciences Ltd (NASDAQ:MYOV)‘s stock had its “buy” rating reiterated by investment analysts at Robert W. Baird in a research report issued on Wednesday. They currently have a $20.00 price target on the stock. Robert W. Baird’s target price indicates a potential upside of 34.32% from the stock’s previous close.
Other equities analysts also recently issued research reports about the stock. Cowen and Company reiterated a “buy” rating on shares of Myovant Sciences in a report on Tuesday. Zacks Investment Research upgraded shares of Myovant Sciences from a “sell” rating to a “hold” rating in a report on Thursday, September 7th. Finally, Evercore ISI assumed coverage on shares of Myovant Sciences in a report on Wednesday, August 16th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Myovant Sciences currently has a consensus rating of “Buy” and an average target price of $20.00.
Shares of Myovant Sciences (NASDAQ MYOV) traded down 3.87% during mid-day trading on Wednesday, hitting $14.89. 26,781 shares of the stock were exchanged. The stock has a 50-day moving average price of $13.64 and a 200 day moving average price of $13.64. The firm’s market cap is $905.97 million. Myovant Sciences has a 52-week low of $10.25 and a 52-week high of $18.85.
TRADEMARK VIOLATION NOTICE: “Robert W. Baird Reiterates “Buy” Rating for Myovant Sciences Ltd (MYOV)” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/robert-w-baird-reiterates-buy-rating-for-myovant-sciences-ltd-myov/1613548.html.
Hedge funds and other institutional investors have recently modified their holdings of the company. Emory University acquired a new stake in shares of Myovant Sciences during the 2nd quarter worth approximately $1,512,000. JPMorgan Chase & Co. grew its stake in shares of Myovant Sciences by 30.6% during the 1st quarter. JPMorgan Chase & Co. now owns 83,070 shares of the company’s stock worth $975,000 after purchasing an additional 19,474 shares during the period. RA Capital Management LLC grew its stake in shares of Myovant Sciences by 56.6% during the 1st quarter. RA Capital Management LLC now owns 2,348,422 shares of the company’s stock worth $27,570,000 after purchasing an additional 848,422 shares during the period. Wells Fargo & Company MN grew its stake in shares of Myovant Sciences by 331.9% during the 1st quarter. Wells Fargo & Company MN now owns 16,527 shares of the company’s stock worth $194,000 after purchasing an additional 12,700 shares during the period. Finally, BB Biotech AG grew its stake in shares of Myovant Sciences by 0.4% during the 2nd quarter. BB Biotech AG now owns 3,317,171 shares of the company’s stock worth $38,811,000 after purchasing an additional 14,336 shares during the period.
Myovant Sciences Company Profile
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.